TECLens Secures $9.3M Series A Funding to Revolutionize Vision Correction with Non-Invasive CXL Technology

TECLens, Inc., a trailblazer in clinical-stage ophthalmic medical devices, is excited to announce a successful funding round of $9,300,000—an investment that marks a significant leap forward in our mission to revolutionize refractive vision care. This substantial infusion of capital will expedite the development and commercialization of our pioneering non-invasive corneal cross-linking technology, uniquely embodied in the CXLens® system. By combining a single-use disposable contact lens with a state-of-the-art control unit that incorporates real-time ultrasound feedback and patterned UV light delivery, our innovative platform is set to transform how refractive errors, particularly presbyopia, are treated. Our focus on presbyopia—through our proprietary quantitative cross-linking (qCXL™) technology—promises a comfortable, in-office procedure that restores near vision for patients seeking alternatives to conventional solutions. The new funding will not only bolster the clinical development and validation of qCXL™ for presbyopia but will also support the exploration of additional applications, including treatments for hyperopia, progressive myopia in children, low-order myopia in adults, and keratoconus. With this financial backing, TECLens is well-positioned to accelerate research, enhance our device technology, and expand our clinical trials across diverse populations. By pushing the boundaries of minimally invasive and personalized care, our goal is to offer life-long therapeutic and refractive solutions that improve visual outcomes globally. We are proud to welcome new partners on this journey to redefine advanced vision correction and deliver transformative care to patients around the world.